Levi Rice, DO
Interventional Cardiology · Durango, CONPI 1306176235
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,991 of the $15,923 with a category attached, or 69.0%. 38 manufacturers reported payments, led by Abbott at 25.8% of the total.
Across 364 payments — averaging $43.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Medtronic$3K
- Boston Scientific$2K
- Penumbra, Inc.$2K
- Novartis$684
- Amgen$522
- plus $4K from 32 others
What the payments were for
- Consulting fees$1181%
- Travel & lodging$4,52728%
- Food & beverage$10,99169%
- Education$2121%
- Gifts$750%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 89 | $4,104 |
| Medtronic(2 entities) | 33 | $2,957 |
| Boston Scientific | 22 | $2,212 |
| Penumbra, Inc. | 4 | $1,658 |
| Novartis | 36 | $684 |
| Amgen | 27 | $522 |
| Johnson & Johnson | 29 | $426 |
| Abiomed | 6 | $424 |
| AstraZeneca | 17 | $379 |
| Merck | 15 | $312 |
| Shockwave Medical, Inc | 13 | $298 |
| Biotronik Inc. | 3 | $272 |
| Astellas Pharma US Inc | 5 | $246 |
| E.r. Squibb & Sons, L.L.C. | 11 | $203 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $190 |
| Cardiovascular Systems Inc. | 5 | $188 |
| Pfizer | 6 | $167 |
| Sanofi-aventis U.S. LLC | 7 | $117 |
| Chiesi USA, Inc. | 3 | $99 |
| Novo Nordisk | 4 | $76 |
| Esperion Therapeutics, Inc. | 3 | $52 |
| Cvrx, Inc. | 2 | $41 |
| Philips North America LLC | 2 | $36 |
| Edwards Lifesciences | 1 | $29 |
| Daiichi Sankyo Inc. | 1 | $27 |
| La Jolla Pharmaceutical Company | 1 | $22 |
| Bardy Diagnostics, Inc. | 1 | $20 |
| Bard Peripheral Vascular, Inc. | 1 | $19 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $19 |
| Atricure, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Vital Connect, Inc | 1 | $16 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Terumo Medical Corporation | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Scpharmaceuticals Inc. | 1 | $13 |
| Cook Medical LLC | 1 | $12 |
| Acist Medical Systems, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$1,658
- ONYX FRONTIER$1,645
- Omnilink Elite vascular stent system$1,168
- EMBLEM$1,138
- Xience Sierra Coronary Stent System$449
- GENERAL - THERAPIES$334
- Impella$282
- AVEIR$230
- Confirm Rx$188
- XIENCE SIERRA$156
- LATITUDE Communicator Power Supply$139
- ENSITE$138
- Rivacor$128
- Solia$128
- BioMonitor$128
- Edora$128
- Acticor$128
- FARXIGA$125
- SYMPLICITY G3$116
- Reveal LINQ$113
How this compares
$15,923 in reported general payments places this provider in the 65th percentile of 111 interventional cardiology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 174 | $147,896 |
| EntrestoSacubitril/Valsartan | 77 | $73,989 |
| BrilintaTicagrelor | 78 | $50,790 |
| FarxigaDapagliflozin Propanediol | 35 | $29,094 |
| XareltoRivaroxaban | 21 | $22,788 |
| Repatha SureclickEvolocumab | 16 | $18,136 |
| Ranolazine ErRanolazine | 56 | $4,098 |
| Metoprolol Succinate | 199 | $2,214 |
| Prasugrel Hcl | 20 | $1,547 |
| ClopidogrelClopidogrel Bisulfate | 156 | $1,487 |
| Rosuvastatin Calcium | 93 | $1,445 |
| Carvedilol | 192 | $1,329 |
| Atorvastatin Calcium | 148 | $975 |
| Amlodipine Besylate | 121 | $785 |
| Nifedipine ErNifedipine | 20 | $728 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $167 | $147,896174 claims |
| AstraZenecaBrilinta, Farxiga | $379 | $79,884113 claims |
| NovartisEntresto | $684 | $73,98977 claims |
| Johnson & JohnsonXarelto | $426 | $22,78821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 111 interventional cardiology providers in Colorado.
Other interventional cardiology in Durango
- Ehrin ArmstrongEnglewood$718K
- Gareth MorganAurora$536K
- Jamaluddin MolooAurora$272K
- Jenny Zablah AlabiAurora$269K
- Srinivas IyengarBoulder$254K
- Nima AghiliLakewood$220K
- Sridhar Sampath-KumarAurora$142K
- Matthew ZipseAurora$137K
- Jeffrey ParkAurora$132K
- Qaisar KhanThornton$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.